NCT04086823: A trial that was reported late by Raziel Therapeutics Ltd.
This trial has reported, although it was 648 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04086823 |
|---|---|
| Title | A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers. |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 25, 2020 |
| Completion date | Sept. 16, 2020 |
| Required reporting date | Sept. 16, 2021, midnight |
| Actual reporting date | June 26, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 648 |